The discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases

Bibliography

• Sen S, Chakraborty R. The role of antioxidants in human health. American chemical society. In: Andreescu S, Hepel M, editors, Oxidative stress: diagnostics, prevention, and therapy; ACS symposium series. American Chemical Society, Washington, DC; 2011. p. 1-37
   Google Scholar
• Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-85
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
   PubMed Web of Science ®Google Scholar
• Bargagli E, Olivieri C, Bennett D, et al. Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respir Med 2009;103:1245-56
   PubMed Web of Science ®Google Scholar
• Kinnula VL, Fattman CL, Tan RJ, Oury T. Oxidative stress in pulmonary fibrosis. Am J Respir Crit Care Med 2005;172:417-22
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biol Med 2010;49:1603-16
   PubMed Web of Science ®Google Scholar
• Freeman LR, Keller JN. Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions. Biochim Biophys Acta 2012;1822:822-9
   PubMed Web of Science ®Google Scholar
• Lenz AG, Hinze-Heyn H, Schneider A, et al. Influence of inflammatory mechanisms on the redox balance in interstitial lung disease. Respir Med 2004;98:737-45
   PubMed Web of Science ®Google Scholar
• Tayarani I, Chaudiere J, Lefauconnier JM, Bourre JM. Enzymatic protection against peroxidative damage in isolated brain capillaries. J Neurochem 1987;48:1399-402
   PubMed Web of Science ®Google Scholar
• Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radical Biol Med 1997;23:134-47
   PubMed Web of Science ®Google Scholar
• Lovell MA, Ehmann WD, Butler SM, Markesberg WR. Elevated thiobarbituric acid reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 1995;45:1594-601
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Theinhaus OJ, Bosmann HB. Superoxide dismutase activity in Alzheimer’s disease: possible mechanism for paired helical formation. Brain Res 1989;476:160-2
   PubMed Web of Science ®Google Scholar
• Pappella MA, Omar RA, Kim KS, Rubakis UK. Immunohistochemical evidence of antioxiodant stress in Alzheimer’s disease. Am J Pathol 1992;140:621-8
   PubMedGoogle Scholar
• Frautschy SA, Baired A, Cole GM. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci USA 1991;88:8362-6
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Chyan YJ, Omar RA, et al. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer’s disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998;152:871-7
   PubMed Web of Science ®Google Scholar
• Olivier S. Oxidative stress: a theoretical model or a biological reality? C R Biol 2004;327:649-62
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353-6
   PubMed Web of Science ®Google Scholar
• Walker FO. Huntington’s disease. Semin Neurol 2007;27:143-50
   PubMed Web of Science ®Google Scholar
• The Huntington’s disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993;72:971-83
   PubMed Web of Science ®Google Scholar
• Beal MF. Mitochondria, free radicals and neurodegeneration. Curr Opin Neurobiol 1996;6:661-6
   PubMed Web of Science ®Google Scholar
• Olney JW, Gubareff T. Glutamate neurotoxicity and Huntington’s chorea. Nature 1978;271:557-9
   PubMed Web of Science ®Google Scholar
• Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington’s disease. Brain Pathol 1999;9:147
   PubMed Web of Science ®Google Scholar
• Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol 1997;41:646-53
   PubMed Web of Science ®Google Scholar
• Goebel HH, Heipertz R, Scholz W, et al. Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 1978;28:23-31
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Gardian G, et al. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington’s disease. J Neurochem 2003;86:267-72
   PubMed Web of Science ®Google Scholar
• Rao AV, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 2002;5:291-309
   PubMed Web of Science ®Google Scholar
• Olanow CW. The pathogenesis of cell death in Parkinson’s disease. Mov Disord 2007;22:S335-42
   PubMed Web of Science ®Google Scholar
• Chung KK, Dawson VL, Dawson TM. New insights into Parkinson’s disease. J Neurol 2003;250:III15-24
   PubMedGoogle Scholar
• Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000;1:120-9
   PubMed Web of Science ®Google Scholar
• Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007;208:1-25
   PubMed Web of Science ®Google Scholar
• Przedborski S, Jackson-Lewis V, Vila M, et al. Free radical and nitric oxide toxicity in Parkinson’s disease. Adv Neurol 2003;91:83-94
   PubMed Web of Science ®Google Scholar
• Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004;10:S18-25
   PubMed Web of Science ®Google Scholar
• Danielson SR, Andersen JK. Oxidative and nitrative protein modifications in Parkinson’s disease. Free Radical Biol Med 2008;44:1787-94
   PubMed Web of Science ®Google Scholar
• Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996;93:2696-701
   PubMed Web of Science ®Google Scholar
• Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9:92-7
   PubMed Web of Science ®Google Scholar
• Patel BP, Hamadeh MJ. Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clin Nutr 2009;28:604-17
   PubMed Web of Science ®Google Scholar
• Gonzalez de Aguilar JL, Echaniz-Laguna A, Fergani A, et al. Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem 2007;101:1153-60
   PubMed Web of Science ®Google Scholar
• Carr MT, Ferri A, Cozzolino M, et al. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull 2003;61:365-74
   PubMed Web of Science ®Google Scholar
• Bonnefont-Rousselot D, Lacomblez L, Jaudon MC, et al. Blood oxidative stress in amyotrophic lateral sclerosis. J Neurol Sci 2000;178:57-62
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62
   PubMed Web of Science ®Google Scholar
• Bogdanov MB, Ramos LE, Xu Z, Beal MF. Elevated ‘‘hydroxyl radical’’ generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 1998;71:1321-4
   PubMed Web of Science ®Google Scholar
• Hand CK, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve 2002;25:135-59
   PubMed Web of Science ®Google Scholar
• Bogdanov M, Brown HR, Matson W, et al. Increased oxidative damage to DNA in ALS patients. Free Radical Biol Med 2000;29:652-8
   PubMed Web of Science ®Google Scholar
• Rizzardini M, Lupi M, Bernasconi S, et al. Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. J Neurol Sci 2003;207:51-8
   PubMed Web of Science ®Google Scholar
• Shibata N, Nagai R, Uchida K, et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001;917:97-104
   PubMed Web of Science ®Google Scholar
• Beal MF. Mitochondria and the pathogenesis of ALS. Brain 2000;123:1291-2
   PubMed Web of Science ®Google Scholar
• Guegan C, Vila M, Rosoklija G, et al. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001;21:6569-76
   PubMed Web of Science ®Google Scholar
• Glade MJ. Oxidative stress and cognitive longevity. Nutrition 2010;26:595-603
   PubMed Web of Science ®Google Scholar
• Corbetta M, Patel G, Shulman GL. The reorienting system of the human brain: from environment to theory of mind. Neuron 2008;58:306-24
   PubMed Web of Science ®Google Scholar
• Radak Z, Kumagai S, Nakamoto H, Goto S. 8-Oxoguanosine and uracil repair of nuclear and mitochondrial DNA in red and white skeletal muscle of exercise-trained old rats. J Appl Physiol 2007;102:1696-701
   PubMed Web of Science ®Google Scholar
• Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-a-lipoic acid. Proc Natl Acad Sci USA 2002;99:2356-61
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Singh J, Gould TD, et al. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry 2004;9:756-76
   PubMed Web of Science ®Google Scholar
• Byron KY, Bitanihirwe TWW. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011;35:878-93
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant T, Welham J. Schizophrenia: a concise overview of incidence, prevalance, and mortality. Epidemiol Rev 2008;30:67-76
   PubMed Web of Science ®Google Scholar
• Radonjic NV, Knezevic IV, Vilimanovich U, et al. Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Neuropharmacology 2010;58:739-45
   PubMed Web of Science ®Google Scholar
• Raffa M, Mechri A, Othman LB, et al. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1178-83
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Mukherjee S, Scheffer R, et al. Elevated plasma lipid peroxides at the onset of non affective psychosis. Biol Psychiatry 1998;43:674-9
   PubMed Web of Science ®Google Scholar
• Herken H, Uz E, Ozyurt H, et al. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6:66-73
   PubMed Web of Science ®Google Scholar
• Lohr JB, Underhill S, Moir S, Jeste V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990;28:535-9
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, et al. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003;117:85-8
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001;15:287-310
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001a;62:878-83
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 2003;26:85-102
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-55
   PubMed Web of Science ®Google Scholar
• Horssen JV, Schreibelt G, Drexhage J, et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radical Biol Med 2008;45:1729-37
   PubMed Web of Science ®Google Scholar
• Bruck W, Stadelmann C. The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol 2005;18:221-4
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 2009;31:13-29
   PubMed Web of Science ®Google Scholar
• Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Brain Res Rev 2005;48:185-95
   PubMed Web of Science ®Google Scholar
• Rotrosen J, Adler L, Lohr J, et al. Antioxidant treatment of tardive dyskinesia. Prostaglandins Leukot Essent Fatty Acids 1996;55:77-81
   PubMed Web of Science ®Google Scholar
• Shriqui CL, Bradwejn J, Annable L Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992;149:391-3
   PubMed Web of Science ®Google Scholar
• Migliore L, Coppede F. Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat Res 2009;674:73-84
   PubMed Web of Science ®Google Scholar
• Hosokawa K, Chen P, Lavin MF, Bottle SE. The impact of carboxy nitroxide antioxidants on irradiated ataxia telangiectasia cells. Free Radical Biol Med 2004;37:946-52
   PubMed Web of Science ®Google Scholar
• Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68
   PubMed Web of Science ®Google Scholar
• Gatei M, Shkedy D, Khanna K, et al. Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha lipoic acid. Oncogene 2001;20:289-94
   PubMed Web of Science ®Google Scholar
• Reichenbach J, Schubert R, Schwan C, et al. Antioxidant capacity in patients with ataxia telangiectasia. Clin Exp Immunol 1999;117:535-9
   PubMed Web of Science ®Google Scholar
• Marmolino D. Friedreich’s ataxia: past, present and future. Brain Res Rev 2011;67:311-30
   PubMed Web of Science ®Google Scholar
• Sies H. editior Oxidative stress: oxidants and antioxidants. Academic Press, London, UK; 1991. p. XV-XXII
   Google Scholar
• Reed TT. Lipid peroxidation and neurodegenerative disease. Free Radical Biol Med 2011;51:1302-19
   PubMed Web of Science ®Google Scholar
• Zamocky M, Koller F. Understanding the structure and function of catalases: clues from molecular evolution and in vitro mutagenesis. Prog Biophys Mol Biol 1999;72:19-66
   PubMed Web of Science ®Google Scholar
• Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta 2003;333:19-39
   PubMed Web of Science ®Google Scholar
• Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radical Biol Med 1995;19:227-50
   PubMed Web of Science ®Google Scholar
• Gad MZ. Anti-aging effects of l-arginine. J Adv Res 2010;1:169-77
   Google Scholar
• Smita EN, Muskieta FAJ, Boersma ER. The possible role of essential fatty acids in the pathophysiology of malnutrition: a review. Prostaglandins Leukot Essent Fatty Acids 2004;71:241-50
   PubMed Web of Science ®Google Scholar
• Rao AV, Rao LG. Carotenoids and human health. Pharmacol Res 2007;55:207-16
   PubMed Web of Science ®Google Scholar
• Esposito E, Rotilio D, Matteo VD, et al. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging 2002;23:719-35
   PubMed Web of Science ®Google Scholar
• Williams RJ, Spencer JPE, Rice-Evans C. Flavonoids: antioxidants or signalling molecules? Free Radical Biol Med 2004;36:838-49
   PubMed Web of Science ®Google Scholar
• Palace VP, Khaper N, Qin Q, Singal PK. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Free Radical Biol Med 1999;26:746-61
   PubMed Web of Science ®Google Scholar
• Kim DO, Lee KW, Lee HJ, Lee CY. Vitamin C equivalent antioxidant capacity (VCEAC) of phenolic phytochemicals. J Agric Food Chem 2002;50:3713-17
   PubMed Web of Science ®Google Scholar
• Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radical Biol Med 2007;43:4-15
   PubMed Web of Science ®Google Scholar
• Yossi GS, Eldad M, Daniel O. Oxidative stress induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001;40:959-75
   PubMed Web of Science ®Google Scholar
• Vatassery GT, Vitamin E. Neurochemistry and implication for Parkinson’s disease. Ann N Y Acad Sci 1992;669:92-110
   Google Scholar
• Sano M, Erresto C, Thomas RG, et al. A controlled trial of selegiline, alpha tocopherol or both as treatment for Alzheimer’s disease. N Engl J Med 1997;336:1216-22
   PubMed Web of Science ®Google Scholar
• Dexter DT, Nanayakkaral A, Goss-Sampson MA. Nigral dopaminergic loss in vitamin E deficient rats. Neuroreport 1994;5:1773-6
   PubMed Web of Science ®Google Scholar
• Cadet JL, Katz M, Jackson-Lewis V, Fahn S. Vitamin E attenuates the toxic effects of intrastriated injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 1989;476:10-15
   PubMed Web of Science ®Google Scholar
• Perumal AS, Gopal VB, Tordzro WK, et al. Vitamin E attenuates the toxic effects of 6-hydoxydopamine on free radical scavenging system in rat brain. Brain Res Bull 1992;29:699-701
   PubMed Web of Science ®Google Scholar
• Tanner C. Epidemiology of Parkinson’s disease. Neurol Clin 1992;10:317-27
   PubMedGoogle Scholar
• Peyser CE, Folstein M, Chase GA, et al. Trial of α-tocopherol in Huntington’s disease. Am J Psychiatry 1995;152:1771-5
   PubMed Web of Science ®Google Scholar
• Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996;57:167-73
   PubMed Web of Science ®Google Scholar
• Rose RC, Bote AM. Biology of free radical scavengers: an evaluation of ascorbate. FASEB J 1993;7:1135-42
   PubMed Web of Science ®Google Scholar
• Agus DB, Sanjiv SG, Pardridge WM, et al. Vitamin C crosses the blood brain barrier in the oxidized form through the glucose transporters. J Clin Invest 1997;100:2842-8
   PubMed Web of Science ®Google Scholar
• Morris MC, Bechett LA, Scherr PA, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer’s Disease. Alzheimer Dis Assoc Disord 1998;12:121-6
   PubMed Web of Science ®Google Scholar
• Masaki KH, White LR, Petrovitch H, et al. The influence of prior and concurrent use of aspirin and vitamins on cognitive function scores in elderly Japanese American men. Neurobiol Aging 1994;1:574
   Google Scholar
• Macdonald PN, Boh D, Ong DE. Localization of cellular retinol binding protein and retinol-binding protein in cells comprising the blood brain barrier of rat and human. Proc Natl Acad Sci USA 1990;87:4265-9
   PubMed Web of Science ®Google Scholar
• Patmanatha ND. Effects of vitamin A and its analogs on nonenzymatic lipid peroxidation in rat brain mitochondria. J Neurochem 1989;52:585-8
   PubMed Web of Science ®Google Scholar
• Stoll S, Rostoch A, Bartsch R, et al. The potent free radical scavenger alpha-lipoic acid improves cognition in rodents. Ann N Y Acad Sci 1994;717:122-8
   PubMed Web of Science ®Google Scholar
• Greenmayere JT, Garcia-Osuna N, Greene JG. The endogenous cofactors, thioctic acid lesions and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum. Neurosci Lett 1994;171:17-20
   PubMed Web of Science ®Google Scholar
• Packer L, Tritschler H, Wessel K. Neuroprotection by the metabolic antioxidant and α-lipoic acid. Free Radical Biol Med 1997;22:359-78
   PubMed Web of Science ®Google Scholar
• Rice-Evans C. Flavonoid antioxidants. Curr Med Chem 2001;8:797-807
   PubMed Web of Science ®Google Scholar
• Schroeter H, Williams RJ, Matin R, et al. Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low- density lipoprotein. Free Radical Biol Med 2000;29:1222-33
   PubMed Web of Science ®Google Scholar
• Koh SH, Lee SM, Kim HY, et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett 2006;395:103-7
   PubMed Web of Science ®Google Scholar
• Ortega-Arellano HF, Jimenez-Del-Rio M, Velez-Pardo C. Life span and locomotor activity modification by glucose and polyphenols in Drosophila melanogaster chronically exposed to oxidative stress-stimuli: implications in Parkinson’s disease. Neurochem Res 2011;36:1073-86
   PubMed Web of Science ®Google Scholar
• Zhang L, Cao H, Wen J, Xu M. Green tea polyphenol (−) epigallocatechin-3- gallate enhances the inhibitory effect of huperzine A on acetylcholinesterase by increasing the affinity with serum albumin. Nutr Neurosci 2009;12:142-8
   PubMed Web of Science ®Google Scholar
• Chang-Mu C, Jen-Kun L, Shing-Hwa L, Shoei-Yn LS. Characterization of neurotoxic effects of NMDA and the novel neuroprotection by phytopolyphenols in mice. Behav Neurosci 2010;124:541-53
   PubMed Web of Science ®Google Scholar
• Wang CY, Zheng W, Wang T, et al. Huperzine A activates Wnt/beta-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. Neuropsychopharmacol 2011;36:1073-89
   PubMed Web of Science ®Google Scholar
• Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neurosignals 2005;14:71-82
   PubMed Web of Science ®Google Scholar
• Ma X, Tan C, Zhu D, et al. Huperzine A from Huperzia species- an ethnopharmacolgical review. J Ethnopharmacol 2007;113:15-34
   PubMed Web of Science ®Google Scholar
• Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006;27:1-26
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang X, Chen Q, et al. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. Zhonghua Yi Xue Za Zhi 2002;82:941-4
   PubMedGoogle Scholar
• Chang-Mu C, Jen-Kun L, Shing-Hwa L, Shoei-Yn LS. Characterization of neurotoxic effects of NMDA and the novel neuroprotection by phytopolyphenols in mice. Behav Neurosci 2010;124:541-53
   PubMed Web of Science ®Google Scholar
• Campos-Esparza MR, Sanchez-Gomez MV, Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium 2009;45:358-68
   PubMed Web of Science ®Google Scholar
• Riviere C, Richard T, Vitrac X, et al. New polyphenols active on beta-amyloid aggregation. Bioorg Med Chem Lett 2008;18:828-31
   PubMed Web of Science ®Google Scholar
• Vingtdeux V, Giliberto L, Zhao H, et al. AMP activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010;285:9100-13
   PubMed Web of Science ®Google Scholar